Paper28840010
Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review.
D'Ambrosio L and 7 others. J Thorac Dis, 2017. Cited by 34 papers, by iCite.
Cite this record
ConductScience Library. Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review. Papers, record 28840010. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/28840010
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Delamanid and bedaquiline to treat multidrug-resistant and extensively drug-resistant tuberculosis in children: a systematic review.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References41
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 17868596 | First tuberculosis cases in Italy resistant to all tested drugs. | Euro Surveill | 2007 | https://conductscience.org/library/papers/17868596 | PubMed |
| 2 | 19494215 | The diarylquinoline TMC207 for multidrug-resistant tuberculosis. | N Engl J Med | 2009 | https://conductscience.org/library/papers/19494215 | PubMed |
| 3 | 19621072 | Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. | PLoS Med | 2009 | https://conductscience.org/library/papers/19621072 | PubMed |
| 4 | 21828024 | WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update. | Eur Respir J | 2011 | https://conductscience.org/library/papers/21828024 | PubMed |
| 5 | 21885418 | Linezolid safety, tolerability and efficacy to treat multidrug- and extensively drug-resistant tuberculosis. | Eur Respir J | 2011 | https://conductscience.org/library/papers/21885418 | PubMed |
| 6 | 22267754 | Tuberculosis: cost of illness in Germany. | Eur Respir J | 2012 | https://conductscience.org/library/papers/22267754 | PubMed |
| 7 | 22379150 | On linezolid efficacy and tolerability. | Eur Respir J | 2012 | https://conductscience.org/library/papers/22379150 | PubMed |
| 8 | 22496332 | Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis. | Eur Respir J | 2012 | https://conductscience.org/library/papers/22496332 | PubMed |
| 9 | 22670901 | Delamanid for multidrug-resistant pulmonary tuberculosis. | N Engl J Med | 2012 | https://conductscience.org/library/papers/22670901 | PubMed |
| 10 | 22997218 | Efficacy and safety of meropenem-clavulanate added to linezolid-containing regimens in the treatment of MDR-/XDR-TB. | Eur Respir J | 2013 | https://conductscience.org/library/papers/22997218 | PubMed |
| 11 | 23018916 | Delamanid improves outcomes and reduces mortality in multidrug-resistant tuberculosis. | Eur Respir J | 2013 | https://conductscience.org/library/papers/23018916 | PubMed |
| 12 | 23060633 | Drug resistance beyond extensively drug-resistant tuberculosis: individual patient data meta-analysis. | Eur Respir J | 2013 | https://conductscience.org/library/papers/23060633 | PubMed |
| 13 | 23075177 | Linezolid for treatment of chronic extensively drug-resistant tuberculosis. | N Engl J Med | 2012 | https://conductscience.org/library/papers/23075177 | PubMed |
| 14 | 23100499 | Resistance to fluoroquinolones and second-line injectable drugs: impact on multidrug-resistant TB outcomes. | Eur Respir J | 2013 | https://conductscience.org/library/papers/23100499 | PubMed |
| 15 | 23813314 | Linezolid to treat extensively drug-resistant TB: retrospective data are confirmed by experimental evidence. | Eur Respir J | 2013 | https://conductscience.org/library/papers/23813314 | PubMed |
| 16 | 23949960 | Costs of tuberculosis disease in the European Union: a systematic analysis and cost calculation. | Eur Respir J | 2014 | https://conductscience.org/library/papers/23949960 | PubMed |
| 17 | 24833763 | ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use. | Eur Respir J | 2014 | https://conductscience.org/library/papers/24833763 | PubMed |
| 18 | 25140958 | Multidrug-resistant tuberculosis and culture conversion with bedaquiline. | N Engl J Med | 2014 | https://conductscience.org/library/papers/25140958 | PubMed |
| 19 | 25552734 | Linezolid to treat MDR-/XDR-tuberculosis: available evidence and future scenarios. | Eur Respir J | 2015 | https://conductscience.org/library/papers/25552734 | PubMed |
| 20 | 25552740 | Low minimal inhibitory concentrations of linezolid against multidrug-resistant tuberculosis strains. | Eur Respir J | 2015 | https://conductscience.org/library/papers/25552740 | PubMed |
Cited by17
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 34 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41498239 | Synthesis, Docking, and Biological Studies of Pyrazine Derivatives as Antimycobacterial Agents. | Med Chem | 2025 | https://conductscience.org/library/papers/41498239 | PubMed |
| 38420252 | Multilevel Pre-extensively Drug-resistant Tubercular Spondylodiscitis: Underdiagnosed or Overlooked? A Case Report. | J Orthop Case Rep | 2024 | https://conductscience.org/library/papers/38420252 | PubMed |
| 38193667 | Identification and optimization of pyridine carboxamide-based scaffold as a drug lead for Mycobacterium tuberculosis. | Antimicrob Agents Chemother | 2024 | https://conductscience.org/library/papers/38193667 | PubMed |
| 37384221 | Advances of new drugs bedaquiline and delamanid in the treatment of multi-drug resistant tuberculosis in children. | Front Cell Infect Microbiol | 2023 | https://conductscience.org/library/papers/37384221 | PubMed |
| 36684898 | Editorial: Updates on tuberculosis control and management. | Front Public Health | 2022 | https://conductscience.org/library/papers/36684898 | PubMed |
| 35458755 | Synthesis and Antimycobacterial Evaluation of N-(4-(Benzyloxy)benzyl)-4-aminoquinolines. | Molecules | 2022 | https://conductscience.org/library/papers/35458755 | PubMed |
| 35404075 | Delamanid Added to an Optimized Background Regimen in Children with Multidrug-Resistant Tuberculosis: Results of a Phase I/II Clinical Trial. | Antimicrob Agents Chemother | 2022 | https://conductscience.org/library/papers/35404075 | PubMed |
| 35245659 | Delamanid-containing regimens and multidrug-resistant tuberculosis: A systematic review and meta-analysis. | Int J Infect Dis | 2022 | https://conductscience.org/library/papers/35245659 | PubMed |
| 35178252 | Research Questions and Priorities for Pediatric Tuberculosis: A Survey of Published Systematic Reviews and Meta-Analyses. | Tuberc Res Treat | 2022 | https://conductscience.org/library/papers/35178252 | PubMed |
| 34067732 | Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid. | Microorganisms | 2021 | https://conductscience.org/library/papers/34067732 | PubMed |
| 31729908 | Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline. | Am J Respir Crit Care Med | 2019 | https://conductscience.org/library/papers/31729908 | PubMed |
| 31650321 | Why Wait? The Case for Treating Tuberculosis with Inhaled Drugs. | Pharm Res | 2019 | https://conductscience.org/library/papers/31650321 | PubMed |
| 31047750 | Dual-targeting GroEL/ES chaperonin and protein tyrosine phosphatase B (PtpB) inhibitors: A polypharmacology strategy for treating Mycobacterium tuberculosis infections. | Bioorg Med Chem Lett | 2019 | https://conductscience.org/library/papers/31047750 | PubMed |
| 31038653 | International collaboration among medical societies is an effective way to boost Latin American production of articles on tuberculosis. | J Bras Pneumol | 2019 | https://conductscience.org/library/papers/31038653 | PubMed |
| 30889995 | New insight into structure-activity of furan-based salicylate synthase (MbtI) inhibitors as potential antitubercular agents. | J Enzyme Inhib Med Chem | 2019 | https://conductscience.org/library/papers/30889995 | PubMed |
| 29933627 | New Chromane-Based Derivatives as Inhibitors of Mycobacterium tuberculosis Salicylate Synthase (MbtI): Preliminary Biological Evaluation and Molecular Modeling Studies. | Molecules | 2018 | https://conductscience.org/library/papers/29933627 | PubMed |
| 29791553 | Epidemiological aspects, clinical manifestations, and prevention of pediatric tuberculosis from the perspective of the End TB Strategy. | J Bras Pneumol | 2018 | https://conductscience.org/library/papers/29791553 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/28840010
GET https://conductscience.org/api/papers/v1/28840010/references?page=2